To assess the sensitivity and accuracy of diffusion magnetic resonance imaging (MRI), including diffusion-weighted imaging (DWI) metrics, in identifying early-stage changes in brain white matter related to various white matter diseases.
Adults aged 18-80 years.
Clinical suspicion of early-stage white matter disease.
No prior diagnosis of significant neurological disorders (e.g., stroke, brain tumors).
Ability to provide informed consent.
Pregnancy or breastfeeding.
Contraindications for magnetic resonance imaging (MRI) (e.g., metal implants, pacemakers).
Severe psychiatric or cognitive impairment that prevents participation.
Control Group: Healthy individuals without any clinical history of neurological diseases, matched by age and sex to the patient cohort.
This study will be a multicenter, cross-sectional study will be conducted on patients diagnosed with suspected early-stage white matter disease (e.g., multiple sclerosis, small vessel disease, Alzheimer's disease, frontotemporal dementia, leukoaraiosis) will be enrolled. Healthy age-matched controls will also be included for comparison.
Cohort
Cross-sectional
Magnetic Resonance Imaging (MRI)
Other interventionMagnetic Resonance Imaging (MRI) Scanner: All imaging will be performed using a 1.5 tesla MRI scanner to ensure high resolution and signal-to-noise ratio.
Sensitivity of diffusion magnetic resonance imaging
Sensitivity of diffusion magnetic resonance imaging to predict the early evaluation of brain white matter diseases
Click on the lead sponsor to view all of their trials.
